OpenAI acquires Orchestra Bio for drug-development AI agents
Original title: OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
Orchestra will fold into Rosalind; terms were not disclosed, and OpenAI already works with Novo Nordisk and Moderna.
OpenAI acquired Orchestra Bio, a startup that helps pharmaceutical teams coordinate drug development, and will fold it into Rosalind, its life-sciences platform. GPT-Rosalind analyzes biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools. The combined effort aims to build agents that link findings with clinical trials and next steps. Financial terms were not disclosed.
Unconfirmed: Financial terms of the acquisition were not disclosed.
- Orchestra agents track trials and flag timelines after events such as a failed batch.
- OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
- Developing a drug in the US takes ten to 15 years on average, the report says.
- Vendors
- OpenAI
- Products
- RosalindRosalind Workbench
- Organizations
- Orchestra BioNovo NordiskModerna
- Countries
- United States
- AI models
- GPT-Rosalind
From the original article
1 min read at the-decoder.com
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average.
By Manuel Uth · the-decoder.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.